ABCLAbCellera Biologics Inc
$5.24
$0.03
(0.57%)
Closed $5.24
$0.08
(1.53%)
After Hours
EarningsAug 6
Mkt Cap$1.6B
Vol2.96M
Fundamentals
Mkt Cap
$1.6B
Volume
-
52W High
$6.79
52W Low
$2.75
PE Ratio
-10.93
Avg. Volume
9.48M
EPS (Annual)
-$0.4901
Rev/Employee
$133,679.72
Earnings
Aug 06
22
Extremely Bearish Sentiment
How do you feel about ABCL?
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
AbCellera (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients...
Business Wire
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Zacks
After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
Zacks
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Zacks
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +36.36% and +68.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2026 and positive interim results from the Phase 1 portion of its ongoing Phase 1/2 clinical trial of ABCL635...
Business Wire
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
ABSCI CORP (ABSI) delivered earnings and revenue surprises of +5.00% and -90.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>